Soleus Capital Master Fund, L.P. 13D and 13G filings for C4 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 3:30 pm Purchase | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 6,603,996 9.400% | 4,048,000 (+158.37%) | Filing |
| 2024-02-05 10:24 am Purchase | 2024-01-26 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 2,555,996 5.200% | 720,000 (+39.22%) | Filing |
| 2024-02-02 09:34 am Sale | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 1,835,996 3.700% | -626,024 (-25.43%) | Filing |
| 2023-04-14 5:07 pm Purchase | 2023-04-13 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 2,462,020 5.000% | 2,462,020 (New Position) | Filing |